|About||To bring immediate non-invasive risk stratification to patients and physicians to aid in the early detection of lung cancer.|
|Mission||To bring immediate non-invasive help to patients and physicians in life threatening disease and to provide a fair return on investment to shareholders and other stakeholders.|
|Description||ProLung’s mission is to make a difference in time for lung cancer patients. ProLung is a leader in innovative predictive analytics technology and non-invasive biomarkers for the risk stratification of lung cancer. The Company develops, tests, and commercializes solutions which may shorten the time to diagnosis and expand the therapeutic window for lung cancer patients. ProLung’s predictive analytics platform for lung cancer risk stratification is approved for sale in the European Economic Area and for investigational use only in the US.|
The EPN Scanner is only available for purchase in the European Economic Area and European Free Trade Association Countries and for investigational use only in the United States.
For more information, please visit our website: